Fig. 2From: Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastomaVariations of circulating cell-free DNA concentration during treatment. a Median cfDNA concentration (ng/mL of plasma) at baseline is higher than in the control group (healthy subjects) and decreases between baseline and pre-RT-TMZ in both the biopsy group (b) and the tumor resection group (c). RT: radiotherapy; TMZ: temozolomideBack to article page